| protein
| sequestering SUMO1-conjugated MDM2 (UBL1) in the nucleus |
|
preventing binding to TP53 and/or RB1 which results in p53 activation and cell cycle arrest |
|
p14ARF cooperatively activating TP53 with CARF |
|
functional link between CDKN2A and ING1 |
|
expression levels of CDKN2A, CDKN2B, and CDKN2BAS are positively correlated  |
|
CDKN2A-ZNF420 interaction could be induced or enhanced in response to oncogene activation |
|
elevated CDKN2A competed with TP53 to bind to ZNF420, therefore disrupted the ZNF420-TP53 interaction |
|
TRADD shuttles dynamically from the cytoplasm into the nucleus to modulate the interaction between CDKN2A and its E3 ubiquitin ligase TRIP12, thereby promoting CDKN2A stability and tumour suppression |
|
by binding to the RING domain of RNF2, CDKN2A disrupts RNF2 homodimerization, providing a potential mechanism for its effect on RNF2 self-ubiquitination |
|
DLC1 inactivation cooperates with downregulation of CDKN2B and CDKN2A, leading to neoplastic transformation and poor prognosis in cancer |
|
MKRN1 functions as a novel E3 ligase of CDKN2A and potentially regulates cellular senescence and tumorigenesis in gastric cancer |
|
EEF1A2 as a novel interacting partner CDKN2A, and interaction of CDKN2A with EEF1A2, and subsequent downregulation of the expression and function of EEF1A2 is a novel mechanism explaining the anti-proliferative effects of CDKN2A |
|
CARM1 represses replicative senescence by methylating ELAVL1 and thereby enhancing ELAVL1 ability to regulate the turnover of CCNA1, CCNB1, FOS, SIRT1, and CDKN2A mRNAs ( |
|
CDKN2A stabilizes the CDKN1A mRNA through negative regulation of the mRNA decay-promoting HNRNPD protein |
|
TMUB1 acts as a functional bridge in NPM1-CDKN2A interactions |
|
control of CD8 T cell proliferation and terminal differentiation by active STAT5B and CDKN2A/CDKN2B |
|
CDKN2A plays a previously unrecognized role in downregulating KL expression during ageing |
|
VHL/CDKN2A interaction is specifically mediated by the 53 residue long pVHL30 N-terminal region, suggesting that this N-terminus acts as a further VHL interaction interface |
|
TNF activates HUWE1 by inducing the dissociation of HUWE1 from its inhibitor CDKN2A |
|
CDKN2A was recognized by the F-box protein FBXW11 and degraded by the proteasome |
|
CDKN2A/TIMP3 modulation of inflammatory response and vascularization in the context of intervertebral disk degeneration (IVDD) |
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
| deletion
|
|
| |
in osteosarcomas and Ewing sarcomas, and in cutaneous large cells lymphoma (marker of apparition and progression), homozygously deleted in any neuroblastomas and in bladder cancer | | tumoral
|
| LOH
|
|
| |
in esophageal squamous cell carcinoma (concomitant loss of RB or not) and in hepatocellular carcinoma | | tumoral
|
|
|
| loss of function
| |
inactivated by hypermethylation in non small cell lung carcinoma of non-smoker, in melanoma and in pancreas carcinoma | | tumoral
|
|
|
| gain of function
| |
activated by hypomethylation in breast cancer | | tumoral
|
|
|
| loss of function
| |
loss of function or deletion in ovarian granulosa cell | | tumoral
|
| deletion
|
|
| |
-mutated or deleted in non in small cell lung carcinoma of smoker,in squamous cell carcinoma of the skin and esophagus, in vulval squamous neoplasia and in colorectal cancer | | tumoral
| germinal mutation
| deletion
|
|
| |
in melanoma | | tumoral
|
| deletion
|
|
| |
with hypermethylation of CpG islands, in acute lymphoblastic leukemia (ALL) | | tumoral
|
| deletion
|
|
| |
minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large B-cell lymphomas | | tumoral
|
|
| --low
|
| |
by promoter methylation may be closely implicated in the pathogenesis of multiple myeloma (MM) | |
